- **Name:** Victoria Petrides

- **Current Position:** Design Quality Program Manager, Abbott Laboratories

- **Country:** United States

- **Educational Background:**
  - BS, University of Michigan, Ann Arbor MI, USA (1992)
  - MS, University of Cincinnati, Cincinnati OH, USA (1995)

- **Professional Experience:** Abbott Laboratories, Abbott Park IL, USA (1997 – present)
  - Statistician with increasing levels of responsibility as a leader within Abbott's core laboratory division from 1997 to 2020 and within Abbott's corporate quality and regulatory organization from 2020 to the present.
  - Currently responsible for reviewing FDA submissions for all of Abbott's diagnostic divisions, which includes core laboratory, hematology, transfusion, point of care, molecular, and diabetes products.
  - Specializing in *in vitro* diagnostic (IVD) device analytical and clinical study designs.
  - Extensive experience supporting the research and development of core laboratory products for cardiac, cancer, clinical chemistry, and infectious diseases, including SARS-CoV-2.
  - Primary author of 30+ protocol templates demonstrating analytical performance for all phases of IVD assay product life cycle.

- **Professional Organizations:**
  - Charter member, American Statistical Association (ASA) Medical Device and Diagnostic Section
  - Member / Contributor, CLSI EP06, EP07, EP12, EP19, and EP35 document development committees
  - Member, Clinical and Laboratory Standards Institute (CLSI) Consensus Council (2021 – present)
  - Co-chair, AdvaMed Statistical Working Group (2016 – present)
  - Co-organizer, Annual FDA/AdvaMed Statistical Issues Conference (2008 – present)
  - Co-organizer, Annual ASA Biopharmaceutical Statistical Workshop (2005 – 2016)

- **Main Scientific Publications:**
  - CLSI. *Assessment of Equivalence or Suitability of Specimen Types for Medical Laboratory Measurement Procedures*. 1st ed. CLSI guideline EP35. Wayne, PA: Clinical and Laboratory Standards Institute; 2019.
  - **Petrides** V, Schneider S. Using Sigma metrics to establish analytical product performance requirements and optimize analytical performance of an in vitro diagnostic assay using a theoretical total PSA assay as an example. Biochem Med. 2018;28.
  - Orzechowski A, **Petrides** V, Scopp R. Ensuring suitable quality of clinical measurements through design. Clin Biochem. 2018;54:48-55.
  - CLSI. *Interference Testing in Clinical Chemistry*. 3rd ed. CLSI guideline EP07. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.
  - **Petrides V**, Schneider S, Scopp R, Orzechowski A. Uncertainty of measurement and total analytical error: better together. AACC Conference. Chicago, IL. 2018.
  - Westgard S, **Petrides V**, Schneider S, Berman M, Herzogenrath J, Orzechowski A. Assessing precision, bias and sigma-metrics of 53 measurands of the Alinity ci system. Clin Biochem. 2017;50:1216-21.
  - **Petrides V**, El Mubarak HS, Kondratovich M, Meier K, Ye J, Gawel S, Akselrod S, Charnot-Katsikas A, Simon K. Assessing Performance for Assays Reporting Equivocal Results. AACC Conference. Atlanta, GA. 2015.